Outcome measurement in female sexual dysfunction clinical trials: review and recommendations.
about
Flibanserin: a potential treatment for Hypoactive Sexual Desire Disorder in premenopausal women.Regulatory perspective on clinical trials and end points for female sexual dysfunction, in particular, hypoactive sexual desire disorder: formulating recommendations in an environment of evolving clinical science.Topical alprostadil treatment of female sexual arousal disorder.Cues resulting in desire for sexual activity in womenThe sensitivity of event logs, self-administered questionnaires and photoplethysmography to detect treatment-induced changes in female sexual arousal disorder (FSAD) diagnosisPDE5 inhibitors beyond erectile dysfunction.Potential of patient-reported outcomes as nonprimary endpoints in clinical trials.Assessment of sexual function/dysfunction via patient reported outcomes.Sexual dysfunction in women with type 1 diabetes: long-term findings from the DCCT/ EDIC study cohortPatient-Centered Outcomes and Treatment Preferences Regarding Sexual Problems: A Qualitative Study Among Midlife Women.Flibanserin and its discontents.Correlated genetic and non-shared environmental influences account for the co-morbidity between female sexual dysfunctions.Developing treatments for female sexual dysfunction.Assessment of sexuality after hysterectomy using the Female Sexual Function Index.Assessment of sexuality among middle-aged women using the Female Sexual Function Index.[Cross-cultural adaptation of the Female Sexual Function Index].Psychometric properties of the French Female Sexual Function Index (FSFI).
P2860
Q30451936-5D9D9E85-E5E1-4781-A0E8-0A5FFC771886Q33244825-0327A822-C225-4173-AA5F-06D8A855CD7BQ33245951-E860D1C4-2739-4CD5-A39B-AB8492FD8358Q33817135-BC35D7FE-CDB9-43C4-A4BF-454EB0B869D9Q33817983-2C4BF0EC-48A4-4F23-BF16-3456A919A2D9Q36878017-B00D7450-9371-4517-9167-A4A3A20F59B0Q36885222-BDF2ECAF-3BC2-43BD-84AA-6533EB7DADB8Q36912122-1F6604C7-EBCA-42C7-85EA-FBD8574C3400Q37163654-CDDACA5D-0639-4BDD-838A-CD6AF610FFC6Q38710577-8E5B5282-DE5E-4022-87FF-6F72B2C3DB6BQ39011718-19957F81-F9DC-41CD-B1B0-C6354F1DE8B0Q42649359-43BF74A1-0555-4AE3-B9B7-192A065487C8Q44091665-E5BE2F55-5E09-418B-8228-02DF800575F0Q44094210-BEABA51B-4875-44D4-9D97-EFC5569F16FBQ44248426-7487C7D7-0EE9-428C-BA1A-78B7036D6B88Q44612184-D6792965-794C-4F4A-B77F-A639722AE449Q50716040-235F736A-B296-42F6-B653-5F5BF87C6ED6
P2860
Outcome measurement in female sexual dysfunction clinical trials: review and recommendations.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Outcome measurement in female ...... s: review and recommendations.
@ast
Outcome measurement in female ...... s: review and recommendations.
@en
type
label
Outcome measurement in female ...... s: review and recommendations.
@ast
Outcome measurement in female ...... s: review and recommendations.
@en
prefLabel
Outcome measurement in female ...... s: review and recommendations.
@ast
Outcome measurement in female ...... s: review and recommendations.
@en
P2093
P2860
P1476
Outcome measurement in female ...... ls: review and recommendations
@en
P2093
Eric Corty
Leonard DeRogatis
Raymond C Rosen
Stanley E Althof
Tara Symonds
P2860
P304
P356
10.1080/00926230590909989
P577
2005-03-01T00:00:00Z